RNAi Roundtable: ONPATTRO™ (patisiran) for hATTR Amyloidosis with Polyneuropathy* & Investigational ALN-TTRsc02 for the Treatment of ATTR Amyloidosis**

RNAi Roundtable: ONPATTRO™ (patisiran) for hATTR Amyloidosis with Polyneuropathy* & Investigational ALN-TTRsc02 for the Treatment of ATTR Amyloidosis**

On September 11, 2018, we hosted an online RNAi Roundtable to review the progress with ONPATTRO™ (patisiran) and ALN-TTRsc02, RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis*.

Access the replay

View the presentation

Read the transcript

* ONPATTRO is approved in the U.S. for the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults, and in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. **ALN-TTRsc02 is an investigational RNAi therapeutic, in development for the treatment of ATTR amyloidosis. 

  • Eric Green, Vice President, General Manager, TTR Program
  • Michael Sherman, M.D., M.B.A., Chief Medical Officer and Senior Vice President for Health Services, Harvard Pilgrim Health Care
  • Rena Denoncourt, Program Leader, ALN-TTRsc02 Program


Diese Website ist nur für Einwohner in Deutschland bestimmt.